Arovella Therapeutics – executive interview

Published on 22 August 2022

Arovella Therapeutics is an Australian biotechnology company specialised in immunoncology with a focus on the invariant natural killer T (iNKT) cell therapy platform, which was in-licensed from Imperial College London in July 2021. The platform can be combined with chimeric antigen receptors (CARs) to target blood cancers, with a potential of being an allogeneic ‘off-the-shelf’ therapy. This was followed by the in-licensing of a novel monoclonal antibody targeting a Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center in December 2021. Arovella plans to combine the DKK1-targeting technology with the iNKT cell therapy platform in the future. With recent fund-raising activity, we believe the company has sufficient funds for its development activities until CY23.

In this video, CEO Michael Baker provides an update on Arovella’s recent milestones and strategy.

Share this with friends and colleagues